PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate
Demographics (3)
- age - Age at study enrollment (phv00265249.v1.p1)
- sex - Sex (phv00265252.v1.p1)
- SEX - Sex (phv00508191.v1.p1)
Race and Ethnicity (1)
- race - Race (phv00265250.v1.p1)
Other (21)
- ANALYTE_TYPE - Analyte type (phv00265255.v2.p1)
- BODY_SITE - Body site where sample was collected (phv00265254.v2.p1)
- BODY_SITE_CATEGORY - Body site where sample was collected (phv00265264.v2.p1)
- composite_progression - Composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy (12-14 weeks or earlier if progression is suspected). The progression is judged based on PSA levels, radiography estimate progression, and symptoms assessments. (phv00265251.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00265239.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00265262.v2.p1)
- IS_TUMOR - Tumor status (phv00265256.v2.p1)
- PRIMARY_METASTATIC_TUMOR - Primary metastatic tumor (phv00265257.v2.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00265258.v2.p1)
- SAMPLE_ID - De-identified sample ID (phv00265253.v2.p1)
- SAMPLE_ID - Sample ID (phv00265244.v2.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00265245.v2.p1)
- SAMPLE_USE - Sample Use (phv00265247.v2.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00265263.v2.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00265246.v2.p1)
- Stage - Stage (phv00265259.v2.p1)
- SUBJECT_ID - Subject ID (phv00265243.v2.p1)
- SUBJECT_ID - De-identified subject ID (phv00265248.v1.p1)
- SUBJECT_ID - Subject ID (phv00265238.v1.p1)
- TREATMENT_POST_VISIT - Treatment post visit (phv00265261.v2.p1)
- TUMOR_TREATMENT - Tumor treatment (phv00265260.v2.p1)